Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bimatoprost

bimatoprost

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of bimatoprost

10 trials tracked of bimatoprost: 2 in phase 3 or 4.

10Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 7 Other / NA 1
  1. Phase 4 The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye Completed
  2. Phase 3 Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients Completed
  3. Phase 2 Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Completed
  4. Phase 2 A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension Completed
  5. Phase 2 Dose-Ranging Study of the Bimatoprost Ocular Insert Completed
  6. Phase 2 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed
Show 4 more trials
  1. Phase 2 An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert Completed
  2. Phase 2 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed
  3. Phase 2 An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product Completed
  4. N/A A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Netarsudil shows lower IOP reduction but better conjunctival hyperemia profile versus prostaglandin analogues
Ophthalmology Meta-analysis
Netarsudil shows lower IOP reduction but better conjunctival hyperemia profile versus prostaglandin analogues New data shows netarsudil offers a safer option for some glaucoma patients
A Bayesian network meta-analysis found netarsudil ranked lower for IOP reduction but had a more favorable conjunctival hyperemia profile com…
A fresh look at glaucoma drugs shows one option causes less redness while still helping lower eye pressure effectively.
May 14, 2026